Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
KOPRAN
Mr. Surendra Shrikrishna Somani B.Com. · Mumbai, India · 1,156 employees
₹188.07
▼-1.86%Koprane's revenue growth momentum appears resilient, but margin expansion challenges suggest cautious positioning
Exchange
NSI
Currency
INR
Day range
₹185.00 – ₹194.99
52-week range
₹107.00 – ₹219.00
Sector
Healthcare
Industry
Drug Manufacturers - General
AI investment rating
AI analysis80% confidence
Trading near the midpoint of its 1-year range suggests moderate value, considering the robust revenue growth and expanding global presence.
14.1% below the 1-year high · trend down
Hedge-fund memo
Today
Today's decline appears to be part of an existing downtrend from the 52-week high, driven by profit margin disappointments and rising debt levels.
This week
The stock has traded in a relatively narrower price range over the past week, with the day's low not dipping below ₹107, the 52-week low.
This month
The ₹1.86% fall today marks the second negative month in a row, with the stock still holding near its 50% and 200 SMA.
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Neutral
4 headlines · 4 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 0 of 1 recent quarters (EPS actual vs. consensus).
1.78 vs 2.63
-32.32% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| KOPRAN | 9.08B | 35.29 | 4.91% | 15.42% | 35.80% |
| GUFICBIO | 38.50B | 60.09 | 10.14% | 15.71% | 22.80% |
| INDOCO | 19.97B | 637.32 | — |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 499sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Debt management challenges
Mitigation: Focus on improving profitability and debt management
Rise of biosimilars
Mitigation: Diversify product portfolio and geographies
Regulatory hurdles
Mitigation: Strengthen regulatory compliance processes
Business intelligence
Competitive moat
Koprane's presence in emerging markets and strategic relationships with distributors can serve as a competitive moat.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Revenue growth sustenance and margin improvement
Thesis builder
Bull case
Koprane successfully transitions into emerging market opportunities while addressing margin and regulatory challenges.
Base case
Revenue growth stabilizes, but challenges in maintaining margin and debt management could impact growth trajectory.
Bear case
Regulatory hurdles and rising competition lead to significant margin erosion and declining revenue
Time horizon
12-18 months
Est. CAGR
15-25%
Entry (qual.)
Invest when evidence of margin recovery and sustained revenue growth appears
Exit (qual.)
Consider selling at signs of persistent margin weakness or declining revenue
Overall conviction 80%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how KOPRAN fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain KOPRAN for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
Monitor closely for margin recovery and revenue growth sustainment
The CSR Journal·3d ago·Routine corporate social spending
scanx.trade·5d ago·Reports full-year revenue and profit
whalesbook.com·5d ago·Revenue growth, dividend, new capacity
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
| 1.39% |
| 6.80% |
| HIKAL | 26.76B | — | — | 13.16% | 37.30% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹185.00
Resistance (day/52w high)
₹194.99
Volume
88,921
Trend
down
RSI (14)
53
MACD
bearish
MA cross
golden
50-day MA
₹191.74
200-day MA
₹153.84
vs 200-DMA
22.2%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.